Literature DB >> 30082258

Independent impact of extent of coronary artery disease and percutaneous revascularisation on 30-day and one-year mortality after TAVI: a meta-analysis of adjusted observational results.

Fabrizio D'Ascenzo1, Roberto Verardi, Massimiliano Visconti, Federico Conrotto, Paolo Scacciatella, Artur Dziewierz, Giulio G Stefanini, Jean-Michel Paradis, Pierluigi Omedè, Susheel Kodali, Maurizio D'Amico, Mauro Rinaldi, Stefano Salizzoni.   

Abstract

AIMS: The impact of the severity of coronary artery disease (CAD) and percutaneous coronary interventions (PCI) on outcomes after transcatheter aortic valve implantation (TAVI) remains a matter of debate. We therefore performed a meta-analysis to evaluate the impact of CAD, of its severity and of PCI on mortality after TAVI. METHODS AND
RESULTS: All published studies evaluating the impact of CAD on 30-day and one-year mortality after TAVI at multivariable analysis were included. The primary endpoint was the impact of CAD severity (assessed with the SYNTAX score [SS]) on one-year mortality by pooling with logarithmic transformation results of multivariable adjusted effect estimates from each individual study. Secondary endpoints were the impact of the presence of CAD on 30-day and one-year mortality at multivariable analysis and the impact of residual SYNTAX score (rSS) on one-year mortality at multivariable analysis. A total of 8,334 patients with a median age of 81.3 (81-82) years and STS score of 6.2% (IQR 6.0-6.7) from 13 studies were included. Patients with an SS >22 showed higher one-year mortality at multivariable analysis (OR 1.71 [1.24-2.36]). The presence of CAD did not impact on 30-day and one-year mortality at multivariable analysis (respectively, OR 1.57 [0.71-3.46] and OR 1.25 [0.74-2.11]). Regarding PCI, patients with rSS <8 showed lower one-year mortality (OR 0.34 [0.012-0.93]).
CONCLUSIONS: The risk of death after TAVI is closely related to the complexity of CAD. Patients with an SS >22 present higher mortality. SS may represent a useful tool to select patients undergoing TAVI who could benefit from coronary revascularisation. In this regard, reaching an rSS <8 reduced one-year mortality. Randomised controlled trials are needed to confirm these results.

Entities:  

Mesh:

Year:  2018        PMID: 30082258     DOI: 10.4244/EIJ-D-18-00098

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  12 in total

Review 1.  Percutaneous Coronary Intervention Pre-TAVR: Current State of the Evidence.

Authors:  Lukas S Keller; Vassili Panagides; Jules Mesnier; Jorge Nuche; Josep Rodés-Cabau
Journal:  Curr Cardiol Rep       Date:  2022-05-27       Impact factor: 3.955

Review 2.  Evolving Indications of Transcatheter Aortic Valve Replacement-Where Are We Now, and Where Are We Going.

Authors:  Jules Mesnier; Vassili Panagides; Jorge Nuche; Josep Rodés-Cabau
Journal:  J Clin Med       Date:  2022-05-30       Impact factor: 4.964

3.  Impact of coronary revascularization on outcomes of transcatheter aortic valve implantation.

Authors:  Bilge Duran Karaduman; Hüseyin Ayhan; Telat Keleş; Engin Bozkurt
Journal:  Anatol J Cardiol       Date:  2021-04       Impact factor: 1.596

Review 4.  Challenges in Diagnosis and Functional Assessment of Coronary Artery Disease in Patients With Severe Aortic Stenosis.

Authors:  Srdjan Aleksandric; Marko Banovic; Branko Beleslin
Journal:  Front Cardiovasc Med       Date:  2022-03-11

5.  Mid-term outcomes of Sapien 3 versus Perimount Magna Ease for treatment of severe aortic stenosis.

Authors:  Marko P O Virtanen; Markku Eskola; Mikko Savontaus; Tatu Juvonen; Matti Niemelä; Teemu Laakso; Annastiina Husso; Maina P Jalava; Tuomas Tauriainen; Tuomas Ahvenvaara; Pasi Maaranen; Eeva-Maija Kinnunen; Sebastian Dahlbacka; Mika Laine; Timo Mäkikallio; Antti Valtola; Peter Raivio; Stefano Rosato; Paola D'Errigo; Antti Vento; Juhani Airaksinen; Fausto Biancari
Journal:  J Cardiothorac Surg       Date:  2020-06-29       Impact factor: 1.637

6.  Predictors of early mortality after transcatheter aortic valve implantation.

Authors:  Didrik Kjønås; Gry Dahle; Henrik Schirmer; Siri Malm; Jo Eidet; Lars Aaberge; Terje Steigen; Svend Aakhus; Rolf Busund; Assami Rösner
Journal:  Open Heart       Date:  2019-04-23

7.  Clinical and Echocardiographic Parameters Predicting 1- and 2-Year Mortality After Transcatheter Aortic Valve Implantation.

Authors:  Didrik Kjønås; Henrik Schirmer; Svend Aakhus; Jo Eidet; Siri Malm; Lars Aaberge; Rolf Busund; Assami Rösner
Journal:  Front Cardiovasc Med       Date:  2021-12-06

8.  Influence of polyvascular disease on clinical outcome in patients undergoing transcatheter aortic valve implantation via transfemoral access.

Authors:  Masahiro Yamawaki; Yosuke Honda; Kenji Makino; Takahide Nakano; Yasunori Iida; Fumiaki Yashima; Hiroshi Ueno; Kazuki Mizutani; Minoru Tabata; Norio Tada; Kensuke Takagi; Futoshi Yamanaka; Toru Naganuma; Yusuke Watanabe; Masanori Yamamoto; Shinichi Shirai; Kentaro Hayashida
Journal:  PLoS One       Date:  2021-12-02       Impact factor: 3.240

9.  Impact of extent of coronary artery disease and percutaneous revascularization assessed by the SYNTAX score on outcomes following transcatheter aortic valve replacement.

Authors:  Birgid Gonska; Sinisa Markovic; Tilman Stephan; Eva Thoma; Manuel Rattka; Dominik Felbel; Dominik Buckert; Wolfgang Rottbauer
Journal:  BMC Cardiovasc Disord       Date:  2021-11-30       Impact factor: 2.298

Review 10.  Coronary Artery Disease in Patients with Aortic Stenosis and Transcatheter Aortic Valve Implantation: Implications for Management.

Authors:  Antonio Fb de Azevedo Filho; Tarso Ad Accorsi; Henrique B Ribeiro
Journal:  Eur Cardiol       Date:  2021-12-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.